MARKET

VRDN

VRDN

Viridian Therapeutics Inc
NASDAQ
15.92
+0.11
+0.70%
Pre Market: 16.30 +0.38 +2.39% 07:05 03/17 EDT
OPEN
15.93
PREV CLOSE
15.81
HIGH
16.35
LOW
15.81
VOLUME
399
TURNOVER
0
52 WEEK HIGH
27.20
52 WEEK LOW
11.40
MARKET CAP
1.30B
P/E (TTM)
-4.0035
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at VRDN last week (0310-0314)?
Weekly Report · 21m ago
Viridian Therapeutics Announces Inducement Stock Option Grants
NASDAQ · 6d ago
Weekly Report: what happened at VRDN last week (0303-0307)?
Weekly Report · 03/10 11:33
Viridian Therapeutics Enters New $300M Sale Agreement
TipRanks · 03/04 11:32
VIRIDIAN THERAPEUTICS INC - TERMINATES PRIOR $175 MILLION SALE AGREEMENT
Reuters · 03/04 11:01
VIRIDIAN THERAPEUTICS INC - ENTERS $300 MILLION SALE AGREEMENT WITH JEFFERIES
Reuters · 03/04 11:01
Viridian Therapeutics Faces Uncertainty Amid Regulatory Approval Challenges
TipRanks · 03/04 06:01
VIRIDIAN THERAPEUTICS, INC. FORM 10-K
Press release · 03/03 21:25
More
About VRDN
Viridian Therapeutics, Inc. is a biopharmaceutical company focused on engineering and developing potential medicines for patients with serious and rare diseases. The Company is advancing multiple candidates in the clinic for the treatment of patients with thyroid eye disease (TED). The Company is conducting two global Phase 3 clinical trials (THRIVE and THRIVE-2) to evaluate the safety and efficacy of VRDN-001 in patients with active and chronic TED. It is focused on advancing VRDN-001 as a potential intravenous therapy followed by VRDN-003 as a potential subcutaneous therapy for the treatment of TED. Its advanced program, VRDN-001, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED. In addition to its TED portfolio, the Company is advancing a novel portfolio of neonatal Fc receptor (FcRn) inhibitors, including VRDN-006 and VRDN-008, which has the potential to be developed in multiple autoimmune diseases.

Webull offers Viridian Therapeutics Inc stock information, including NASDAQ: VRDN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VRDN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading VRDN stock methods without spending real money on the virtual paper trading platform.